This clinical trial is focused on studying the long-term safety and tolerability of a treatment for Neovascular Age-Related Macular Degeneration (nAMD), a condition that affects the eyes and can lead to vision loss. The treatment being studied involves the use of a medication called Ranibizumab, which is delivered through a special device known as the Port Delivery System. This system allows the medication to be released into the eye over an extended period, potentially reducing the need for frequent injections.

The purpose of the study is to evaluate how safe and well-tolerated this method of delivering Ranibizumab is for patients with nAMD. Participants in the study will receive the treatment every 24 or 36 weeks, depending on the specific group they are assigned to. The study will monitor participants over a long period to gather information on any side effects or issues that may arise from the treatment. This will help researchers understand the potential benefits and risks associated with using the Port Delivery System for managing nAMD.

Throughout the study, participants will undergo regular check-ups to assess their vision and overall eye health. These assessments will help determine any changes in vision and identify any adverse effects related to the treatment. The study aims to provide valuable insights into the long-term use of the Port Delivery System with Ranibizumab for individuals with Neovascular Age-Related Macular Degeneration.